NASDAQ$ORGO
Organogenesis Holdings Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Organogenesis reported Q3 2025, revenue of $95M, net loss of $12M.
For Q3 2025, Organogenesis reported revenue of $95M, a net loss of $12M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $95M.
- Net loss $12M.
- Organogenesis highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Organogenesis · Revenue · Quarterly
$151M
Revenue by segment
Organogenesis · $109M total across 2 segments · Q3 2023
- Advanced Wound Care$101M-7.4%93.4%
- Surgical & Sports Medicine$7.2M-1.4%6.6%
Forward guidance
The release discusses Organogenesis's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Organogenesis cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q3 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+2.8%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+0.5%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+102.3%
Q4 2024
Best reaction
-42.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -6.2% | -5.9% | |
| Q4 2025 | -13.8% | -22.4% | -38.1% | |
| Q3 2025 | +44.1% | +66.6% | +21.9% | |
| Q1 2025 | -42.4% | -43.6% | -43.3% | |
| Q4 2024 | +102.3% | +95.8% | +46.6% | |
| Q3 2024 | +26.6% | +10.3% | +0.9% | |
| Q2 2024 | +2.0% | +6.4% | -1.2% | |
| Q1 2024 | +31.2% | +23.2% | +19.0% | |
| Q4 2023 | -16.3% | -20.3% | -18.6% | |
| Q3 2023 | +6.8% | +22.9% | +62.4% | |
| Q2 2023 | -25.7% | -27.0% | -31.6% | |
| Q1 2023 | +29.7% | +43.2% | +81.1% | |
| Q4 2022 | +11.0% | -2.9% | -13.1% | |
| Q3 2022 | -18.3% | -11.5% | -17.7% | |
| Q2 2022 | -25.2% | -26.6% | -44.0% | |
| Q1 2022 | +4.6% | +9.8% | -9.3% | |
| Q4 2021 | +18.1% | +15.6% | +2.4% | |
| Q3 2021 | -6.4% | -5.0% | -16.1% | |
| Q2 2021 | +1.9% | +2.5% | +8.2% | |
| Q1 2021 | -15.3% | -11.3% | -28.7% | |
| Q4 2020 | +3.8% | +8.5% | +31.4% | |
| Q3 2020 | +8.2% | +5.2% | +20.2% | |
| Q2 2020 | +0.7% | +1.5% | +3.2% | |
| Q1 2020 | -9.9% | -18.8% | +4.2% | |
| Q4 2019 | -16.2% | +11.6% | +23.5% | |
| Q3 2019 | +10.3% | +8.8% | -36.1% | |
| Q2 2019 | -4.7% | -10.8% | +26.5% | |
| Q1 2019 | -0.4% | +1.0% | +0.7% | |
| Q4 2018 | -3.0% | -5.3% | -16.8% | |
| Q4 2017 | -3.0% | -5.3% | -16.8% | |
| Q2 2018 | +0.3% | +0.2% | +0.1% | |
| Q1 2018 | +0.0% | +0.4% | +0.3% | |
| Q3 2017 | +0.1% | +0.1% | -1.0% | |
| Q2 2017 | +0.0% | +0.1% | +1.5% | |
| Q1 2017 | -0.3% | -0.3% | +0.5% | |
| Q4 2016 | +0.0% | +0.0% | +0.0% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro